Trial Profile
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Pitavastatin (Primary)
- Indications Cardiovascular disorders
- Focus Therapeutic Use
- Acronyms REPRIEVE; REPRIEVE; REPRIEVE EU
- 06 Mar 2024 Results evaluating the biological pathways mediating statin effects on NCPvol in REPRIEVE presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
- 06 Mar 2024 Results hypothesizing that physical function would decline among PWH presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
- 02 Jan 2024 Results from biomarker sub study examining associations between CMV IgG titer and physical function in virologically suppressed people with HIV , published in the JAIDS